We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Qiagen Buys Australian Biotech Company, Expands Molecular Diagnostics Portfolio

By LabMedica International staff writers
Posted on 11 Apr 2011
Qiagen (Venlo, The Netherlands) has offered US$355 million to purchase the Australian Biotechnology company, Cellestis (Chadstone, Australia), thus expanding its molecular diagnostics product portfolio. More...


The acquisition will provide Qiagen with access to a dimension in disease detection not currently possible with other diagnostic methods--the QuantiFERON technology that is highly complementary to Qiagen's portfolio.

The premolecular testing technology QuantiFERON has been commercialized by Cellestis together with an already marketed test and its flagship product QuantiFERON-TB Gold In-Tube (QFT) for detection of latent tuberculosis (TB).

In addition, Cellestis is in the early stages of commercializing QuantiFERON-CMV to monitor the disease risk of life-threatening CMV virus. This patent-protected platform technology enables quick detection of the diseases compared to other traditional DNA-based molecular tests.

The acquisition is subject to certain conditions, including Cellestis shareholder approval, regulatory and court approvals, and an independent expert's opinion that the scheme is in the best interests of Cellestis shareholders. A meeting to consider the scheme of arrangement is expected in late June.

Cellestis chairman Ron Pitcher said, "After careful consideration, the Cellestis board has unanimously concluded that the offer represents an attractive price for Cellestis and provides shareholders with an opportunity to realize considerable value from their investment in Cellestis."

"The offer price recognizes the significant value within Cellestis Quantiferon technology, which the management team and staff at Cellestis have developed into a global leading technology in the diagnosis of latent tuberculosis."

Related Links:
Qiagen
Cellestis


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Mumps Test
ReQuest MUMPS IgM Assay
New
Clostridium Difficile Test
Immunocard Toxins A&B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Results of AI-based 3D virtual H&E staining and quantitative analysis of pathological tissue (Photo courtesy of Nature Communications, DOI:10.1038/s41467-025-59820-0)

Virtual Staining Technology Paves Way for Non-Invasive Pathological Diagnosis

For more than 200 years, traditional pathology has depended on the technique of examining cancer tissues under a microscope, a method that provides only limited, specific cross-sections of the 3D structure... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.